Green Leaf Pharmaceuticals' new generation NTRK inhibitor LPM4870108 tablets are about to enter the clinic.

NTRK gene fusion is a clear cancer-causing driver, widely distributed in different types of cancer, and is found in more than 20 adult and child solid tumors, including lung cancer, colorectal cancer, thyroid tumors, fibroids, and so on.
the first generation of NTRK and target products are considered by the industry as a "broad-spectrum" anti-cancer drug that targets precision, treating cancer based on tumor genetics rather than the primary site of the tumor, providing new therapeutic hope for patients with solid tumors who are in particular advanced or metastasized and lack other effective treatment options.
unfortunately, most NTRK fusion-positive cancer patients have been treated with the first generation of NTRK with the target products for a period of time, there have been acquired drug resistance mutations, including NTRK1-G595R, NTRK2-G639R, NTRK3-G623R, etc., and there is no second generation inhibitors approved for the above mutations.
LPM4870108 is a synthetic and highly selective second-generation NTRK inhibitor found by Green Leaf Pharmaceuticals, which is effective for both wild and acquired drug-resistant mutations and is intended to be used for the treatment of "NTRK gene fusion and its drug-resistant mutation-positive solid tumor patients."
LPM4870108 is expected to cover all related indications of the first generation of targeted products that are listed, as well as treatment of first-generation inhibitors with congenital resistance or acquired drug resistance after drug use, i.e. first- and second-line therapy for patients with NTRK gene fusion solid tumors, with a wider range of indications.
.